Investors may have missed OncoMed Pharmaceuticals (OMED) in the flurry of biotech IPOs this year, but last week's pop was more than enough to raise a few eyebrows. Shares soared more than 80% after the company announced a deal with big biotech Celgene (CELG). In the following video, analysts Simon Erickson and Max Macaluso discuss the details of the deal, what it means for both OncoMed and Celgene, and whether partnerships like this will be a continuing trend in the biotech space.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
What OncoMed's Deal With Celgene Means for Investors
A look at Celgene's latest deal with OncoMed, a small biotech that went public just a few months ago.
Max Macaluso, Ph.D. owns shares of Celgene. Simon Erickson has no position in any stocks mentioned. The Motley Fool recommends Celgene. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned


*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.